Drugs / BMS-986405
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04855136 | Jun 2021 → Apr 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04036461 | Aug 2019 → Jul 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04036461 ↗ |
| Action | Inhibit | “gamma secretase inhibitor (GSI)” NCT04855136 ↗ |
| Route | Oral | “BMS-986405 will be administered orally.” NCT04036461 ↗ |